Trevena Stock Price, News & Analysis (NASDAQ:TRVN)

$1.65 0.09 (5.77 %)
(As of 12/15/2017 04:00 PM ET)
Previous Close$1.65
Today's Range$1.54 - $1.65
52-Week Range$1.35 - $8.00
Volume1.85 million shs
Average Volume816,573 shs
Market Capitalization$104.18 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.58

About Trevena (NASDAQ:TRVN)

Trevena logoTrevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.

Receive TRVN News and Ratings via Email

Sign-up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorBio Therapeutic Drugs
SymbolNASDAQ:TRVN
CUSIPN/A
Phone+1-610-3548840

Debt

Debt-to-Equity Ratio0.38%
Current Ratio4.92%
Quick Ratio4.92%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.75 million
Price / Sales27.41
Cash FlowN/A
Price / CashN/A
Book Value$1.41 per share
Price / Book1.17

Profitability

Trailing EPS($1.65)
Net Income$-102,990,000.00
Net MarginsN/A
Return on Equity-150.22%
Return on Assets-94.66%

Miscellaneous

Employees72
Outstanding Shares62,300,000

Trevena (NASDAQ:TRVN) Frequently Asked Questions

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

How were Trevena's earnings last quarter?

Trevena Inc (NASDAQ:TRVN) posted its quarterly earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.06. During the same quarter in the prior year, the business posted ($0.57) earnings per share. View Trevena's Earnings History.

When will Trevena make its next earnings announcement?

Trevena is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Trevena.

Where is Trevena's stock going? Where will Trevena's stock price be in 2017?

10 analysts have issued twelve-month price targets for Trevena's stock. Their forecasts range from $2.50 to $15.00. On average, they anticipate Trevena's stock price to reach $8.65 in the next year. View Analyst Ratings for Trevena.

What are Wall Street analysts saying about Trevena stock?

Here are some recent quotes from research analysts about Trevena stock:

  • 1. According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (11/2/2017)
  • 2. Needham & Company LLC analysts commented, "Trevena announced 1Q17 financial results yesterday. Olinvo NDA submission in pain still on track for 4Q17. Phase 3 open-label ATHENA safety trial has reached 600pt enrollment. Company therefore likely to reach target 1100 pt exposures per FDA recommendation (~480pts treated in APOLLO trials) in near future. As a reminder, Olinvo Phase 3 APOLLO trials did not establish consistent statistically significant differentiation from morphine on secondary GI and respiratory endpoints. We believe observed trend was clinically meaningful, but have updated our models to reflect modest market penetration given likely challenges in communicating differentiation." (5/5/2017)
  • 3. Cowen Inc analysts commented, "TRVN reported 4Q16 results." (3/22/2017)
  • 4. HC Wainwright analysts commented, "Following the Phase 3 pivotal APOLLO readouts, and the subsequent ~45% drop in TRVN shares (vs. -1.5% NBI) over the last two trading sessions, we assess the implications of the mixed data set, and suggest likely/ probable clinical settings for use that best match OLINVO's (new brand name for oliceridine) overall therapeutic profile' we believe some physicians may find OLINVO useful at reducing antiemetic use, especially in hard tissue pain (most commonly, knee and hip surgery). Yet despite a more nuanced view than some, we nonetheless acknowledge that APOLLO results are far from the "clean win" we were hoping for." (2/23/2017)
  • 5. Aegis analysts commented, "After presenting results yesterday, Trevena finished the trading day down approximately 40%. We believe there are several contributing factors: (1) the lowest dose 0.1 mg did not prove non-inferiority to that of morphine; (2) on the safety side, improvements on the respiratory and nausea/vomiting measurement did not show statistical significance to that of Morphine; (3) investors may think that the current data set points to an Oliceridine that has no commercial value proposition relative to that of morphine. This could lead to slow market adoption; (4) the company may need a capital raise before the NDA is accepted. If a capital raise is completed with current share price, this may lead to excessive dilution; (5) the Athena open label study may be a little behind schedule which puts further pressure on cash runway of the company. We will be buyers on weakness. We view the situation quite differently. The most important thing in our eye's is that Trevena is likely to have enough data for an NDA in 4Q17 after the Athena trial is completed." (2/22/2017)

Who are some of Trevena's key competitors?

Who are Trevena's key executives?

Trevena's management team includes the folowing people:

  • Leon O. Moulder Jr., Independent Chairman of the Board (Age 59)
  • Maxine Gowen Ph.D., President, Chief Executive Officer, Director (Age 59)
  • Roberto E. Cuca, Chief Financial Officer, Senior Vice President (Age 47)
  • Michael W. Lark Ph.D., Senior Vice President - Research, Chief Scientific Officer (Age 57)
  • John M. Limongelli Esq., Senior Vice President, General Counsel, Corporate Secretary (Age 46)
  • Carrie L. Bourdow, Senior Vice President, Chief Commercial Officer (Age 54)
  • Yacoub Habib Ph.D., Senior Vice President - Business Development and Corporate Planning
  • David Soergel M.D., Senior Vice President - Clinical Development , Chief Medical Officer (Age 47)
  • Michael R. Dougherty, Independent Director (Age 59)
  • Adam M. Koppel M.D. Ph.D., Independent Director (Age 47)

Who owns Trevena stock?

Trevena's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Northpointe Capital LLC (2.15%), Dimensional Fund Advisors LP (1.57%), GSA Capital Partners LLP (0.15%) and Bourgeon Capital Management LLC (0.14%). Company insiders that own Trevena stock include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Institutional Ownership Trends for Trevena.

Who sold Trevena stock? Who is selling Trevena stock?

Trevena's stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP. View Insider Buying and Selling for Trevena.

Who bought Trevena stock? Who is buying Trevena stock?

Trevena's stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Northpointe Capital LLC and Bourgeon Capital Management LLC. Company insiders that have bought Trevena stock in the last two years include Carrie L Bourdow, Maxine Gowen and Yacoub Habib. View Insider Buying and Selling for Trevena.

How do I buy Trevena stock?

Shares of Trevena can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Trevena's stock price today?

One share of Trevena stock can currently be purchased for approximately $1.65.

How big of a company is Trevena?

Trevena has a market capitalization of $104.18 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-102,990,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Trevena employs 72 workers across the globe.

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Blvd Ste 200, CHESTERBROOK, PA 19087-5625, United States. The biopharmaceutical company can be reached via phone at +1-610-3548840 or via email at [email protected]


MarketBeat Community Rating for Trevena (TRVN)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  357 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Trevena (NASDAQ:TRVN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.923.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.71$9.71$11.27$12.86
Price Target Upside: 445.41% upside445.41% upside385.89% upside291.99% upside

Trevena (NASDAQ:TRVN) Consensus Price Target History

Price Target History for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ:TRVN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017OppenheimerReiterated RatingBuy$5.00N/AView Rating Details
11/8/2017HC WainwrightReiterated RatingBuy$5.00N/AView Rating Details
11/8/2017Needham & Company LLCLower Price TargetBuy$9.00 -> $7.00N/AView Rating Details
10/16/2017BarclaysDowngradeOverweight -> Equal Weight$15.00 -> $2.50N/AView Rating Details
8/4/2017CowenReiterated RatingBuy$10.00MediumView Rating Details
5/6/2017Roth CapitalSet Price TargetBuy$9.00MediumView Rating Details
4/17/2017AegisReiterated RatingBuy$14.00LowView Rating Details
3/11/2017FBR & CoSet Price TargetBuy$8.00HighView Rating Details
2/16/2017Jefferies GroupReiterated RatingBuy$11.00N/AView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$15.00N/AView Rating Details
12/1/2016WedbushReiterated RatingOutperform$16.00N/AView Rating Details
10/25/2016Brean CapitalSet Price TargetBuy$14.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00N/AView Rating Details
3/2/2016WallachBeth CapitalInitiated CoverageBuy$18.00N/AView Rating Details
(Data available from 12/16/2015 forward)

Earnings

Trevena (NASDAQ:TRVN) Earnings History and Estimates Chart

Earnings by Quarter for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ TRVN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018($0.27)N/AView Earnings Details
11/7/2017Q3 2017($0.33)($0.27)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.35)($0.35)ViewN/AView Earnings Details
5/4/2017Q1 2017($0.55)($0.36)ViewN/AView Earnings Details
3/8/2017Q4 2016($0.62)($0.67)$0.48 millionViewListenView Earnings Details
11/3/2016Q3 2016($0.40)($0.57)$1.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.35)$1.93 million$1.88 millionViewN/AView Earnings Details
3/9/2016Q415($0.26)($0.30)$1.64 million$1.88 millionViewListenView Earnings Details
11/10/2015Q3($0.34)($0.24)$1.80 million$1.88 millionViewN/AView Earnings Details
8/11/2015Q215($0.37)($0.28)$1.30 million$1.88 millionViewN/AView Earnings Details
5/7/2015($0.33)($0.33)$10.00 million$0.63 millionViewN/AView Earnings Details
3/18/2015Q414($0.39)($0.45)ViewN/AView Earnings Details
11/11/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/12/2014($0.35)($0.44)ViewN/AView Earnings Details
5/9/2014Q114($0.36)($0.59)$0.03 million$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Trevena (NASDAQ:TRVN) Earnings Estimates

2017 EPS Consensus Estimate: ($1.64)
2018 EPS Consensus Estimate: ($0.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.56)($0.38)($0.48)
Q2 20174($0.54)($0.36)($0.43)
Q3 20174($0.50)($0.21)($0.37)
Q4 20174($0.54)($0.17)($0.36)
Q1 20182($0.18)($0.16)($0.17)
Q2 20182($0.17)($0.16)($0.17)
Q3 20182($0.21)($0.16)($0.19)
Q4 20182($0.26)($0.16)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Trevena (NASDAQ:TRVN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Trevena (NASDAQ TRVN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 56.26%
Insider Trades by Quarter for Trevena (NASDAQ:TRVN)
Institutional Ownership by Quarter for Trevena (NASDAQ:TRVN)

Trevena (NASDAQ TRVN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/9/2016Carrie L BourdowSVPBuy4,000$4.34$17,360.00View SEC Filing  
11/7/2016Maxine GowenCEOBuy12,500$4.10$51,250.00View SEC Filing  
11/7/2016Yacoub HabibSVPBuy5,000$4.12$20,600.00View SEC Filing  
5/27/2016Maxine GowenCEOBuy22,084$7.12$157,238.08View SEC Filing  
12/10/2015David SoergelCMOSell27,217$10.55$287,139.35View SEC Filing  
12/12/2014John M LimongelliVPBuy3,000$4.14$12,420.00View SEC Filing  
12/10/2014Enterprise Associates 12 NewMajor ShareholderBuy1,000,000$4.00$4,000,000.00View SEC Filing  
12/10/2014Maxine GowenCEOBuy8,000$4.00$32,000.00View SEC Filing  
12/10/2014Michael R DoughertyDirectorBuy7,000$4.00$28,000.00View SEC Filing  
12/10/2014Michael W LarkVPBuy5,000$4.00$20,000.00View SEC Filing  
12/10/2014Roberto CucaCFOBuy25,000$4.00$100,000.00View SEC Filing  
12/9/2014Leon O Moulder JrDirectorBuy30,200$3.96$119,592.00View SEC Filing  
9/29/2014Rosamond DeeganSVPSell44$7.00$308.00View SEC Filing  
2/5/2014Laboratories Holdings L ForestMajor ShareholderBuy428,571$7.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Trevena (NASDAQ TRVN) News Headlines

Source:
DateHeadline
Head-To-Head Survey: Trevena (TRVN) and Forward Pharma A/S (FWP)Head-To-Head Survey: Trevena (TRVN) and Forward Pharma A/S (FWP)
www.americanbankingnews.com - December 8 at 11:30 PM
Trevena, Inc. (TRVN) Receives Average Recommendation of "Buy" from BrokeragesTrevena, Inc. (TRVN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 30 at 3:40 AM
Research Analysts Set Expectations for Trevena, Inc.s Q1 2018 Earnings (TRVN)Research Analysts Set Expectations for Trevena, Inc.'s Q1 2018 Earnings (TRVN)
www.americanbankingnews.com - November 14 at 9:26 AM
Trevena, Inc. (TRVN) Earns "Buy" Rating from Oppenheimer Holdings, Inc.Trevena, Inc. (TRVN) Earns "Buy" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 13 at 2:27 PM
Trevena, Inc. (TRVN) Expected to Announce Earnings of -$0.26 Per ShareTrevena, Inc. (TRVN) Expected to Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - November 12 at 9:30 AM
Trevena, Inc. (TRVN) Given Buy Rating at HC WainwrightTrevena, Inc. (TRVN) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - November 8 at 10:26 PM
Trevena, Inc. (TRVN) Announces Quarterly  Earnings ResultsTrevena, Inc. (TRVN) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 3:02 PM
Edited Transcript of TRVN earnings conference call or presentation 7-Nov-17 1:00pm GMTEdited Transcript of TRVN earnings conference call or presentation 7-Nov-17 1:00pm GMT
finance.yahoo.com - November 7 at 8:42 PM
Trevena Reports Third Quarter 2017 Financial Results and Announces New Positive Clinical Trial DataTrevena Reports Third Quarter 2017 Financial Results and Announces New Positive Clinical Trial Data
finance.yahoo.com - November 7 at 12:27 PM
Trevena reports 3Q lossTrevena reports 3Q loss
finance.yahoo.com - November 7 at 12:27 PM
Trevena, Inc. (TRVN) Receives Average Recommendation of "Buy" from AnalystsTrevena, Inc. (TRVN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 5 at 4:08 AM
Trevena Announces Submission of New Drug Application to U.S. FDA for OLINVO™ (oliceridine injection)Trevena Announces Submission of New Drug Application to U.S. FDA for OLINVO™ (oliceridine injection)
finance.yahoo.com - November 2 at 10:06 AM
Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech MoversNeurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers
finance.yahoo.com - November 2 at 10:06 AM
Trevena to Report Third Quarter 2017 Financial Results on November 7, 2017Trevena to Report Third Quarter 2017 Financial Results on November 7, 2017
finance.yahoo.com - November 1 at 9:52 AM
Interesting TRVN Call Options For June 2018Interesting TRVN Call Options For June 2018
www.thestreet.com - October 27 at 4:53 PM
Trevena (TRVN) Says it Presented OLINVO Clinical Data at ASATrevena (TRVN) Says it Presented OLINVO Clinical Data at ASA
www.streetinsider.com - October 26 at 11:08 PM
Trevena (TRVN) Says it Presented OLINVO Clinical Data at ASA - StreetInsider.comTrevena (TRVN) Says it Presented OLINVO Clinical Data at ASA - StreetInsider.com
www.streetinsider.com - October 25 at 8:19 PM
Trevena Announces Publication and Presentations of OLINVO™ (oliceridine injection) Clinical DataTrevena Announces Publication and Presentations of OLINVO™ (oliceridine injection) Clinical Data
finance.yahoo.com - October 25 at 8:19 PM
Trevena, Inc. (TRVN) Scheduled to Post Quarterly Earnings on WednesdayTrevena, Inc. (TRVN) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:36 AM
Zacks: Analysts Anticipate Trevena, Inc. (TRVN) Will Post Earnings of -$0.27 Per ShareZacks: Analysts Anticipate Trevena, Inc. (TRVN) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - October 23 at 8:23 AM
Why I See Trevena Going To Zero - Seeking AlphaWhy I See Trevena Going To Zero - Seeking Alpha
seekingalpha.com - October 18 at 9:44 AM
HC Wainwright Lowers Trevena, Inc. (TRVN) Price Target to $7.00HC Wainwright Lowers Trevena, Inc. (TRVN) Price Target to $7.00
www.americanbankingnews.com - October 15 at 7:56 AM
Oppenheimer Holdings, Inc. Analysts Give Trevena, Inc. (TRVN) a $5.00 Price TargetOppenheimer Holdings, Inc. Analysts Give Trevena, Inc. (TRVN) a $5.00 Price Target
www.americanbankingnews.com - October 12 at 6:26 PM
After-Hours Movers 10/11: (ARDX) (BW) (SIGM) Higher; (JILL) (TRVN) (PTGX) Lower (more...)After-Hours Movers 10/11: (ARDX) (BW) (SIGM) Higher; (JILL) (TRVN) (PTGX) Lower (more...)
www.streetinsider.com - October 11 at 9:12 PM
Chesco biopharm firm cuts 21 jobs as part of restructuringChesco biopharm firm cuts 21 jobs as part of restructuring
finance.yahoo.com - October 11 at 9:12 PM
Interesting TRVN Call Options For November 17thInteresting TRVN Call Options For November 17th
www.thestreet.com - October 11 at 4:08 PM
Trevena Announces Restructuring to Focus Resources on Commercial StrategyTrevena Announces Restructuring to Focus Resources on Commercial Strategy
finance.yahoo.com - October 11 at 4:08 PM
Trevena, Inc. (TRVN) Receives Consensus Rating of "Buy" from BrokeragesTrevena, Inc. (TRVN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 11 at 4:50 AM
-$0.31 EPS Expected for Trevena, Inc. (TRVN) This Quarter-$0.31 EPS Expected for Trevena, Inc. (TRVN) This Quarter
www.americanbankingnews.com - October 4 at 2:36 PM
Trevena To Present at the Ladenburg Thalmann 3rd Annual 2017 Healthcare Conference - GlobeNewswire (press release)Trevena To Present at the Ladenburg Thalmann 3rd Annual 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 24 at 8:31 AM
Financial Comparison: Flex Pharma (FLKS) vs. Trevena (TRVN)Financial Comparison: Flex Pharma (FLKS) vs. Trevena (TRVN)
www.americanbankingnews.com - September 19 at 2:48 PM
Trevena, Inc. (TRVN) Given Consensus Recommendation of "Buy" by AnalystsTrevena, Inc. (TRVN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 16 at 4:42 AM
Trevena (TRVN) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowTrevena (TRVN) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 14 at 11:40 AM
Trevena Announces Presentations during PAINWeek® 2017 - GlobeNewswire (press release)Trevena Announces Presentations during PAINWeek® 2017 - GlobeNewswire (press release)
globenewswire.com - September 8 at 3:29 PM
Trevena Announces Presentations during PAINWeek® 2017Trevena Announces Presentations during PAINWeek® 2017
finance.yahoo.com - September 8 at 9:32 AM
Trevena to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceTrevena to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 6 at 9:26 AM
Trevena, Inc. (TRVN) Earns "Buy" Rating from Cowen and CompanyTrevena, Inc. (TRVN) Earns "Buy" Rating from Cowen and Company
www.americanbankingnews.com - August 4 at 1:48 PM
Trevena, Inc. (TRVN) Posts  Earnings Results, Hits ExpectationsTrevena, Inc. (TRVN) Posts Earnings Results, Hits Expectations
www.americanbankingnews.com - August 3 at 9:21 PM
Trevena Reports Second Quarter 2017 Financial Results and Provides Corporate UpdateTrevena Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 3 at 8:08 AM
Trevena reports 2Q lossTrevena reports 2Q loss
finance.yahoo.com - August 3 at 8:08 AM
Trevena, Inc. (NASDAQ:TRVN) Given Consensus Rating of "Buy" by BrokeragesTrevena, Inc. (NASDAQ:TRVN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 28 at 9:39 AM
Trevena, Inc. (TRVN) Scheduled to Post Earnings on WednesdayTrevena, Inc. (TRVN) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:49 AM
Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire (press release)
globenewswire.com - July 22 at 9:53 AM
Trevena To Host 2017 Analyst Day and Announce Results of ATHENA Open Label Safety Study of OLINVOTrevena To Host 2017 Analyst Day and Announce Results of ATHENA Open Label Safety Study of OLINVO
finance.yahoo.com - July 21 at 8:04 AM
Trevena, Inc. (TRVN) Expected to Post Earnings of -$0.36 Per ShareTrevena, Inc. (TRVN) Expected to Post Earnings of -$0.36 Per Share
www.americanbankingnews.com - July 20 at 6:24 PM
Trevena to Host Analyst Day on July 20, 2017 - GlobeNewswire (press release)Trevena to Host Analyst Day on July 20, 2017 - GlobeNewswire (press release)
globenewswire.com - July 14 at 9:21 PM
Trevena to Host Analyst Day on July 20, 2017Trevena to Host Analyst Day on July 20, 2017
finance.yahoo.com - July 13 at 10:43 AM
This $3 Biotech Stock Is Making an 11% Move ThursdayThis $3 Biotech Stock Is Making an 11% Move Thursday
finance.yahoo.com - July 13 at 10:43 AM
Stemline Therapeutics (STML) vs. Trevena (TRVN) Head to Head SurveyStemline Therapeutics (STML) vs. Trevena (TRVN) Head to Head Survey
www.americanbankingnews.com - July 4 at 8:16 PM
Trevena (TRVN) Says Two Posters at ASRA Highlight Positive Phase 3 Data Comparing OLINVO with Intravenous MorphineTrevena (TRVN) Says Two Posters at ASRA Highlight Positive Phase 3 Data Comparing OLINVO with Intravenous Morphine
www.streetinsider.com - April 7 at 6:08 PM

SEC Filings

Trevena (NASDAQ:TRVN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Trevena (NASDAQ:TRVN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Trevena (NASDAQ TRVN) Stock Chart for Saturday, December, 16, 2017

Loading chart…

This page was last updated on 12/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.